A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-50
SponsorSunshine Lake Pharma Co., Ltd.

About this trial

Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib and the safety of the combination therapy in healthy participants.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Informed consents were signed voluntarily with full understanding of the trial content, process and possible adverse reactions. Be able to complete the trial according to the requirements of the trial protocol.

Have no plans of fertility, sperm retrieval or egg donation during the trial, and are willing to take effective contraceptive measures within 6 months from the date of signing ICF to the end of drug administration.

Male or female participants aged 18 to 50 years old (including 18 and 50 years old).

Male participants weighed at least 50 kg and female participants weighed at least 45 kg. Body mass index (BMI) = weight (kg)/height2 (m2), with BMI in the range of 18 to 28 kg/m2 (including cutoff).

Disqualifiers

During the screening period, physical examination, vital signs, laboratory tests(blood routine, blood biochemistry, coagulation function, urine routine), chest X-ray, abdominal ultrasound (liver, gallbladder, pancreas, spleen and kidney), ophthalmic examination and other examinations were abnormal and had clinical significance.

QTcF was calculated with Fridericia's correction formula QTcF = QT/RR (RR^0.33=60/ heart rate (BPM)) in patients with abnormal 12-lead electrocardiogram (ECG) or corrected QT interval (QTcF) >450 ms.

Any positive of hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, or treponema pallidum antibody.

The female participants were pregnant or lactating, and the blood pregnancy results at screening and admission exceeded the upper limit of the normal value.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Clifutinib

    Drug

    The subjects are required to take Clifutinib on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.

  • Itraconazole

    Drug

    Itraconazole is taken orally approximately 30 minutes after the start of breakfast and lunch.

  • fluconazole

    Drug

    Take fluconazole on an empty stomach

  • efavirenz

    Drug

    Take efavirenz on an empty stomach

Treatment groups

80 Participants
are divided into 4 treatment groups
Group A: ClifutinibExperimental treatment 1 intervention
Group B: Clifutinib and ItraconazoleActive comparator 2 interventions
Group C: Clifutinib and FluconazoleActive comparator 2 interventions
Group D: Clifutinib and EfavirenzActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Cmax

Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib in healthy participants.

Time frame
From Day1 to Day50
2

AUC0-t

Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib in healthy participants.

Time frame
From Day1 to Day50
3

AUC0-∞

Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib in healthy participants.

Time frame
From Day1 to Day50
4

%AUCex

Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib in healthy participants.

Time frame
From Day1 to Day50

Secondary outcomes

1

Adverse event

Frequency, type and severity of adverse events/serious adverse events.

Time frame
From Day1 to Day50
2

ECG(Electrocardiogram)

Evaluation parameters include heart rate, PR interval, QTcF and QRS interval, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

Time frame
From Day1 to Day50
3

Body temperature

Summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

Time frame
From Day1 to Day50
4

Blood pressure

Summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

Time frame
From Day1 to Day50

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: